PTC Therapeutics (PTCT) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.39
- Estimate
- $0.30
- Surprise
- -229.5%
- Revenue (period 2026-09-30)
- $357.8M
- Score at report (before → after)
- 6.4 → 6.4/10
Revenue source: xbrl.
How the report landed
PTC Therapeutics (PTCT) reported a wider loss than forecast — adjusted EPS of -$0.39 against the $0.30 estimate (a 229.5% shortfall). TrendMatrix's engine moved from Buy (Wait) (6.4/10) to Hold at 6.4/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates PTCT Hold at 6.4/10.
2 of the last 4 quarters beat the estimate; this quarter's -229.5% surprise compares with a -77.3% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Earnings estimates trending UP
What argues against it
- V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3)
- Consecutive earnings misses (2)
- Below 200-MA, MA slope -2.8%/30d (confirmed downtrend)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $64.46
- Price target
- $88.03
- Stop
- $60.06
- Upside to target
- +36.6%
- Reward-to-risk
- 4.2:1
Risk check: trading volume is running 1.5× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-30 — shown for context, not personalized investment advice.
PTCT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $5.38B
- P/E (fwd)
- 27.2
- 52-week range
- $58.80–$90.87
- Off 52-week high
- 29.1%
- RSI (14)
- 49
- Volume vs avg
- 1.50×
- Score today
- 6.4/10